Pages that link to "Q73626815"

The following pages link to Cysteine 230 is essential for the structure and activity of the cytotoxic ligand TRAIL (Q73626815):

Displaying 49 items.

• Crystal structure of sTALL-1 reveals a virus-like assembly of TNF family ligands (Q27637902) (← links)
• Biochemical and Structural Characterization of the Human TL1A Ectodomain , (Q27655906) (← links)
• Apo2L/TRAIL: apoptosis signaling, biology, and potential for cancer therapy (Q28176737) (← links)
• Specificity of molecular recognition learned from the crystal structures of TRAIL and the TRAIL:sDR5 complex (Q28258628) (← links)
• TRAIL-Based High Throughput Screening Reveals a Link between TRAIL-Mediated Apoptosis and Glutathione Reductase, a Key Component of Oxidative Stress Response (Q28548386) (← links)
• TRAIL gene reorganizes the cytoskeleton and decreases the motility of human leukemic Jurkat cells (Q33246453) (← links)
• Engineering a leucine zipper-TRAIL homotrimer with improved cytotoxicity in tumor cells (Q33689870) (← links)
• 5-allyl-7-gen-difluoromethoxychrysin enhances TRAIL-induced apoptosis in human lung carcinoma A549 cells (Q33975484) (← links)
• New insights into apoptosis signaling by Apo2L/TRAIL. (Q34022690) (← links)
• The tumour necrosis factor receptor family: life or death choices (Q34103388) (← links)
• The molecular architecture of the TNF superfamily (Q34109796) (← links)
• Transduction of tumor necrosis factor-related apoptosis-inducing ligand into hematopoietic cells leads to inhibition of syngeneic tumor growth in vivo. (Q34139621) (← links)
• Hepatocyte Death: A Clear and Present Danger (Q34147508) (← links)
• Improvement in the stability and functionality of Nicotiana tabacum produced recombinant TRAIL through employment of endoplasmic reticulum expression and ascorbate buffer mediated extraction strategies (Q34375637) (← links)
• TRAIL/Apo-2L: mechanisms and clinical applications in cancer (Q34482821) (← links)
• Apo2L/TRAIL and its death and decoy receptors (Q34532325) (← links)
• Cloning and Expression of TNF Related Apoptosis Inducing Ligand in Nicotiana tabacum (Q34777770) (← links)
• Targeting death and decoy receptors of the tumour-necrosis factor superfamily (Q34791120) (← links)
• Protein-based therapeutic approaches targeting death receptors (Q35091424) (← links)
• The Biology of TRAIL and the Role of TRAIL-Based Therapeutics in Infectious Diseases (Q35172090) (← links)
• A humanized leucine zipper-TRAIL hybrid induces apoptosis of tumors both in vitro and in vivo (Q35303638) (← links)
• TRAIL and apoptosis induction by TNF-family death receptors. (Q35591708) (← links)
• Monoclonal antibodies against TRAIL. (Q35756860) (← links)
• Modulation of TRAIL signaling complex. (Q35756863) (← links)
• Retinoids and TRAIL: two cooperating actors to fight against cancer (Q35756905) (← links)
• TRAIL and chemotherapeutic drugs in cancer therapy (Q35756909) (← links)
• Hetero-modification of TRAIL trimer for improved drug delivery and in vivo antitumor activities (Q36134152) (← links)
• Membrane-proximal TRAIL species are incapable of inducing short circuit apoptosis signaling: Implications for drug development and basic cytokine biology (Q36645343) (← links)
• Neutrophils and TRAIL: insights into BCG immunotherapy for bladder cancer (Q36961037) (← links)
• Life and death by death receptors (Q37233180) (← links)
• Directing cancer cells to self-destruct with pro-apoptotic receptor agonists (Q37319386) (← links)
• Engineered adenovirus fiber shaft fusion homotrimer of soluble TRAIL with enhanced stability and antitumor activity (Q37482834) (← links)
• Novel treatment option for MUC16-positive malignancies with the targeted TRAIL-based fusion protein Meso-TR3. (Q37520449) (← links)
• Regulation of the human TRAIL gene. (Q38034651) (← links)
• Death receptors as targets in cancer (Q38103591) (← links)
• TRAIL-beta and TRAIL-gamma: two novel splice variants of the human TNF-related apoptosis-inducing ligand (TRAIL) without apoptotic potential (Q38308073) (← links)
• Journey of TRAIL from Bench to Bedside and its Potential Role in Immuno-Oncology. (Q38557486) (← links)
• The adaptor protein FADD and the initiator caspase-8 mediate activation of NF-κB by TRAIL. (Q39253903) (← links)
• A genetically encoded multifunctional TRAIL trimer facilitates cell-specific targeting and tumor cell killing. (Q39689324) (← links)
• Expression of TNF-related apoptosis-inducing ligand (TRAIL) in keratinocytes mediates apoptotic cell death in allogenic T cells (Q39772770) (← links)
• Leachables from saline-containing IV bags can alter therapeutic protein properties (Q43002668) (← links)
• Both HIV-Infected and Uninfected Cells Express TRAILshort, Which Confers TRAIL Resistance upon Bystander Cells within the Microenvironment (Q47269298) (← links)
• Preclinical toxicity of DATR, a recombinant soluble human TRAIL mutant, in rats and cynomolgus monkeys (Q50527664) (← links)
• Construction and characterization of a new TRAIL soluble form, active at picomolar concentrations. (Q55312940) (← links)
• Differential hepatocyte toxicity of recombinant Apo2L/TRAIL versions (Q73704158) (← links)
• Primary immune effects of eukaryotic expression plasmids encoding two hyperactive mutants of human soluble B lymphocyte stimulator (Q81210876) (← links)
• Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy (Q90241548) (← links)
• Molecular Mode of Action of TRAIL Receptor Agonists-Common Principles and Their Translational Exploitation (Q91716512) (← links)
• TRAILblazing Strategies for Cancer Treatment (Q92757990) (← links)